Veru reports positive clinical results from trial in men with metastatic castration-resistant prostate cancer

Veru reports positive clinical results from veru-111 phase 1b/2 trial in men with metastatic castration-resistant prostate cancer, advancing to pivotal phase 3 clinical program.veru inc - veru-111 safe and well tolerated at daily doses 63 mg and lower; no significant neutropenia or neurotoxicity observed.veru inc - in 8 men treated with at least 4 21-day continuous cycles, median duration of tumor response without cancer progression is 10 months.veru inc - 7 of 8 men treated with at least four 21-day continuous cycles still receiving veru-111 treatment without evidence of cancer progression.veru inc - plans to meet with fda next quarter to gain agreement on registration phase 3 clinical trial design for veru-111 in this indication.
VERU Ratings Summary
VERU Quant Ranking